Literature DB >> 6854062

Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis.

H A Verbrugh, W F Keane, J R Hoidal, M R Freiberg, G R Elliott, P K Peterson.   

Abstract

The antibacterial activity of phagocytic cells and opsonins in peritoneal dialysis effluents from 21 patients undergoing chronic peritoneal dialysis (CPD) was studied. Effluents contained an average of 12 x 10(6) cells per liter that were predominantly macrophages. Macrophages phagocytized and killed opsonized Staphylococcus epidermidis, Staphylococcus aureus, and Escherichia coli as efficiently as did polymorphonuclear neutrophils (PMNs) from healthy donors. Macrophage chemiluminescence was one-third of that observed with donor PMNs. In the absence of opsonins, macrophages efficiently phagocytized and killed S. aureus by binding S. aureus cell wall protein A to macrophage surface IgG. Nine (43%) of 21 effluents failed to opsonize S. epidermidis, and none opsonized E. coli. When present, titers of S. epidermidis opsonins were 50- to 100-fold lower than that of normal serum. IgG and C3 concentrations in effluent reflected its opsonic capacity. Macrophages from patients undergoing CPD thus have intact phagocytic and bactericidal functions. However, the low level of opsonic molecules and inadequate numbers of macrophages in the peritoneal cavity may predispose patients undergoing CPD to peritonitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6854062     DOI: 10.1093/infdis/147.6.1018

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Infections associated with indwelling devices: infections related to extravascular devices.

Authors:  G M Dickinson; A L Bisno
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Benefits of low dose immunoglobulin in the treatment of refractory CAPD peritonitis and longevity of technical survival on CAPD.

Authors:  Belda Dursun; Murat Tuncer; Rasih Felek; F Fevzi Ersoy
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Independence of neutrophil respiratory burst oxidant generation from the early cytosolic calcium response after stimulation with unopsonized Candida albicans hyphae.

Authors:  D R Wysong; C A Lyman; R D Diamond
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  Surface phagocytosis and host defence in the peritoneal cavity during continuous ambulatory peritoneal dialysis.

Authors:  D L Gordon; J L Rice; V M Avery
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

5.  Human peritoneal macrophages: clinical models of inflammation and potential targets of antiinflammatory drugs.

Authors:  J H Wilson; I L Bonta
Journal:  Agents Actions       Date:  1986-01

6.  Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity.

Authors:  D L Dunn; R A Barke; N B Knight; E W Humphrey; R L Simmons
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.

Authors:  M Nakamura; W B Weil; D B Kaufman
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

8.  Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids.

Authors:  H A Verbrugh; W F Keane; W E Conroy; P K Peterson
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

9.  Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis.

Authors:  L A Clark; C S Easmon
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

10.  Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis.

Authors:  H van Bronswijk; H A Verbrugh; H C Heezius; J van der Meulen; P L Oe; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.